Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | CNR1 | P21554 | 4/20 | 0.59 |
| ▸ | HPGD | P15428 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | CES2 | O00748 | 1/20 | 0.53 |
| ▸ | CES1 | P23141 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29816274 | 0.86 | CNR1 (0.63) | TSHRCNR1HPGDALDH1A1KMT2A | |
| Hydrochloric Acid SCHEMBL28469010 | 0.85 | CNR1 (0.61) | CNR1HPGDALDH1A1KMT2ACES2 | |
| SCHEMBL3085217 | 0.85 | CES2 (0.52) | TSHRCNR1ALDH1A1MEN1KMT2A | |
| SCHEMBL10126547 | 0.83 | TSHR (0.59) | TSHRCNR1HPGDALDH1A1MEN1 | |
| SCHEMBL4162751 | 0.83 | HPGD (0.62) | TSHRCNR1HPGDALDH1A1MEN1 | |
| SCHEMBL12636528 | 0.83 | TSHR (0.59) | TSHRCNR1HPGDALDH1A1MEN1 | |
| SCHEMBL3089158 | 0.83 | HDAC8 (0.50) | TSHRCNR1ALDH1A1MEN1KMT2A | |
| SCHEMBL14602602 | 0.83 | CNR1 (0.62) | TSHRCNR1ALDH1A1MEN1KMT2A | |
| SCHEMBL3087941 | 0.83 | PARP1 (0.63) | CES2CES1HDAC8 | |
| SCHEMBL31220894 | 0.83 | PARP1 (0.63) | CES2CES1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230110003-A1 | PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) | Valo Health, LLC | 2023-04-13 | — | — | US | disclosed |
| US-11479564-B2 | Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT) | VALO HEALTH, INC. (US) | 2022-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230110003-A1 | PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) | NAMPT, NAPRT, NNMT | TSHR 3065/4885CNR1 1693/4885HPGD 105/4885 |
| US-11479564-B2 | Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT) | NAMPT, NAPRT, NNMT | TSHR 3065/4885CNR1 1693/4885HPGD 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.